Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company headquartered in Tokyo, Japan. Founded in 1781 and incorporated in 1925, Takeda is publicly traded on the Tokyo Stock Exchange and the New York Stock Exchange under the tickers 4502 and TAK, respectively. As one of the largest pharmaceutical companies in Asia, it employs over 47,000 people globally. For the fiscal year ending in March 2025, the company reported revenue of approximately $29.8 billion.

Takeda is a research-based operating company focused on the discovery, development, and commercialization of pharmaceutical drugs. Its core therapeutic areas are oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies, and vaccines. The company's portfolio includes top-selling drugs such as Entyvio for inflammatory bowel diseases and Vyvanse for ADHD. Takeda's global presence expanded significantly following its 2019 acquisition of Shire, which bolstered its capabilities in treating rare diseases.

The company's patent litigation profile is that of an operating company actively enforcing its intellectual property. The database shows Takeda as a plaintiff in its only tracked case and not as a defendant. This posture is consistent with a research-based pharmaceutical company protecting its drug patents from potential infringement by competitors, rather than being a target of non-practicing entities (NPEs).

The company's single tracked suit is Takeda Pharmaceutical Co Ltd v. Qilu Pharmaceutical (hainan) Co Ltd, filed in the District of New Jersey in April 2026. This action against another pharmaceutical manufacturer aligns with Takeda's strategy of defending its key product lines and market position.